Table 1.
CXCR5+CD8+ T cells act as a better prognosticator than CD8+ T cells in MIBC patients.
| Factor | Patients | HR (95% CI) | P | Pinteraction |
|---|---|---|---|---|
| Overall survival | ||||
| All patients | CD8+ T cells (high vs low) | 0.550 (0.377–0.803) | 0.002 | <0.001 |
| CXCR5+CD8+ T cells (high vs low) | 0.279 (0.186–0.420) | <0.001 | ||
| Stage II | CD8+ T cells (high vs low) | 0.775 (0.431–1.395) | 0.396 | 0.008 |
| CXCR5+CD8+ T cells (high vs low) | 0.340 (0.186–0.623) | <0.001 | ||
| Stage III+IV | CD8+ T cells (high vs low) | 0.539 (0.327–0.888) | 0.015 | 0.001 |
| CXCR5+CD8+ T cells (high vs low) | 0.286 (0.161–0.508) | <0.001 | ||
| Disease-free survival | ||||
| All patients | CD8+ T cells (high vs low) | 0.757 (0.513–1.116) | 0.160 | 0.004 |
| CXCR5+CD8+ T cells (high vs low) | 0.431 (0.289–0.644) | <0.001 | ||
| Stage II | CD8+ T cells (high vs low) | 0.818 (0.434–1.543) | 0.536 | 0.044 |
| CXCR5+CD8+ T cells (high vs low) | 0.383 (0.203–0.723) | 0.003 | ||
| Stage III+IV | CD8+ T cells (high vs low) | 0.811 (0.493–1.334) | 0.410 | 0.241 |
| CXCR5+CD8+ T cells (high vs low) | 0.575 (0.338–0.976) | 0.041 | ||
Abbreviations: HR, hazard ratio; CI, confidence interval;
P value < .05 marked in bold font shows statistical significant.